

## (Trifluoromethyl)thiolation of 2-Alkynylbenzoates: An Efficient Route to 4-[(Trifluoromethyl)thio]-1H-isochromen-1-ones

Yuewen Li,<sup>[a]</sup> Guangming Li,<sup>\*[b]</sup> and Qiuping Ding<sup>\*[a]</sup>

Keywords: Fluorine / Sulfur / Cyclization / Alkynes / Oxygen heterocycles / Lewis acid catalysis

The incorporation of the (trifluoromethyl)thio group into the isocoumarin scaffold through a Lewis-acid-mediated electrophilic cyclization reaction of 2-(2-alkynyl)benzoates with trifluoromethanesulfanylamide is reported. The transformation proceeds well in the presence of BiCl<sub>3</sub> and BF<sub>3</sub>·Et<sub>2</sub>O under mild conditions to give 4-[(trifluoromethyl)thio]-1H-isochromen-1-ones regioselectively and in good yields.

#### Introduction

Fluorinated organic compounds often show unique and important physical, chemical, and biological properties due to the high electronegativity, low polarizability, and small size of the fluorine atom, and the strength of the C–F bond. Such compounds have been used to great effect in the pharmaceutical and agrochemical industries.<sup>[1]</sup> Statistical analysis of available data indicates that more than 20% of commercial drugs contain a fluorine group. The trifluoromethylthio group (CF<sub>3</sub>S) has attracted increasing interest because of its strong electron-withdrawing effects and high lipophilicity.<sup>[2]</sup> The introduction of an SCF<sub>3</sub> group into small molecules can enhance their membrane permeability and absorption rate and also their stability. This gives an opportunity for the modification of known and new drugs (Figure 1).<sup>[3]</sup>

Recently, several elegant approaches for the formation of C-SCF<sub>3</sub> bonds by direct trifluoromethylthiolation have been described. Nucleophilic trifluoromethylthiolation reagents (SCF<sub>3</sub><sup>-</sup>),<sup>[4]</sup> such as AgSCF<sub>3</sub>, NMe<sub>4</sub>SCF<sub>3</sub>, and CsSCF<sub>3</sub>, have been used in combination with transition metals (especially, palladium and copper) by Buchwald and Vicic for the efficient formation of C-SCF<sub>3</sub> bonds. Wu and ourselves reported the introduction of the (trifluoromethyl)thio moiety into the scaffold of isoquinoline by using AgSCF<sub>3</sub> as the nucleophilic reagent.<sup>[4e]</sup> Meanwhile, several electrophilic trifluoromethylthiolation reagents ( $SCF_3^+$ ),

- http://chem.jxnu.edu.cn/s/44/t/430/1b/48/info6984.htm
- [b] Department of Gastroenterology, Xinhua Hospital, Medical School of Shanghai Jiaotong University, Shanghai, China E-mail: ligm68@126.com
- Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/ejoc.201402629.



Figure 1. Examples of approved drugs containing an SCF<sub>3</sub> group.

trifluoromethanesulfanylamides,<sup>[5]</sup> trifluoroincluding methylated thioperoxide,<sup>[6]</sup> trifluoromethanesulfonyl hypervalent iodonium ylide,<sup>[7]</sup> and N-trifluoromethylthiophthalimide,<sup>[8]</sup> have been developed to introduce the SCF<sub>3</sub> group into the target products. Recently, Qing and co-workers reported a transition-metal-free oxidative trifluoromethylthiolation of alkynes or arylboronic acids using elemental sulfur and (trifluoromethyl)trimethylsilane (CF<sub>3</sub>TMS) as the source of the (trifluoromethyl)thio group.<sup>[9]</sup> Daugulis and co-workers reported the copper-catalysed single or double trifluoromethylthiolation of 8-aminoquinoline benzamides through the auxiliary-assisted direct functionalization of  $\beta$ -C–H bonds using bis(trifluoromethyl) disulfide (CF<sub>3</sub>S)<sub>2</sub> as the electrophile.<sup>[10]</sup> Radical aryltrifluoromethylthiolation of activated alkenes using an AgSCF<sub>3</sub>/K<sub>2</sub>S<sub>2</sub>O<sub>8</sub> system has also been developed.<sup>[11]</sup>

Isocoumarin and its derivatives can be found in many natural products and pharmaceuticals that show a wide

<sup>[</sup>a] Key Laboratory of Functional Small Organic Molecules, Ministry of Education and College of Chemistry & Chemical Engineering, Jiangxi Normal University, Nanchang, Jiangxi 330022, China E-mail: dqpjxnu@gmail.com

## FULL PAPER

range of physiological and biological activities, such as antibacterial, anti-inflammatory, and anticancer activities, or as protease inhibitors or weedkillers.<sup>[12]</sup> Therefore, a lot of effort has been put into the synthesis of isocoumarins.<sup>[13]</sup> However, the synthesis of fluorinated isocoumarins using fluorinating reagents has not been reported. Prompted by advances in trifluoromethylthiolation, and by our interest in looking for small molecules for the inhibition of the activation and proliferation of hepatic stellate cells, and for the inhibition of extracellular matrix production,<sup>[14]</sup> we envisioned that functionalization of isocoumarin by incorporation of a trifluoromethylthio group under mild conditions would be beneficial for our biological evaluations (Scheme 1). Therefore, we initiated a program for the development of methods that could be used for the synthesis of a library of trifluoromethylthio-substituted isocoumarins.



Scheme 1. Incorporation of an  $SCF_3$  moiety into the isocoumarin core.

### **Results and Discussion**

To examine this proposed trifluoromethylthiolation, we started to explore the practicability of this transformation, and chose the reaction of methyl 2-(phenylethynyl)benzoate (1a) with trifluoromethanesulfanylamide 2 as the model. Based on previous studies, which showed that Lewis acids could promote the electrophilic addition of trifluoromethanesulfanylamide,<sup>[5]</sup> the reaction was initially attempted in the presence of BiCl<sub>3</sub> (1.1 equiv.) or BF<sub>3</sub>·Et<sub>2</sub>O (1.5 equiv.) in ClCH<sub>2</sub>CH<sub>2</sub>Cl (DCE) at 80 °C (Table 1, Entries 1 and 2). However, no reaction took place at all. A trace amount of the desired product (i.e., 3a) was obtained when a combination of Pd(OAc)<sub>2</sub> (10 mol-%) and BiCl<sub>3</sub> (1.1 equiv.) was used (Table 1, Entry 3). The structure of compound 3a was determined by X-ray diffraction analysis (Figure 2). By adjusting the amounts of the three metal salts Pd(OAc)<sub>2</sub> (10 mol-%), BiCl<sub>3</sub> (1.1 equiv.), and BF<sub>3</sub>·Et<sub>2</sub>O (1.5 equiv.), the expected product (i.e., 3a) was obtained in 31% yield (Table 1, Entry 4). We next examined the effect of changing the solvent. The screening results indicated that the reaction in toluene worked more efficiently to give 3a in 38% yield (Table 1, Entries 7-11). We found that the temperature had little impact on the outcome (Table 1, Entries 12-14). Surprisingly, the yield of 3a increased dramatically to 97% in the absence of Pd(OAc)<sub>2</sub> (Table 1, Entry 15). The yield could not be improved further by changing the loading of BiCl<sub>3</sub> or BF<sub>3</sub>·Et<sub>2</sub>O (Table 1, Entries 16 and 17). No reaction occurred when 0.1 equiv. of BiCl<sub>3</sub> was used as the Lewis acid (Table 1, Entry 18).

Table 1. Initial studies for the cyclization of methyl 2-(phenylethynyl)benzoate (1a) with trifluoromethanesulfanylamide  $2^{[a]}$ 



[a] Reaction conditions: methyl 2-(phenylethynyl)benzoate (1a) (0.2 mmol), trifluoromethanesulfanylamide 2a (0.3 mmol), under N<sub>2</sub>. [b] DMA = N,N-dimethylacetamide. [c] Isolated yield based on 1a; n.r. = no reaction; n.d. = no 3a detected. [d] Under air.



Figure 2. ORTEP representation of the structure of 4-[(trifluoromethyl)thio]-1*H*-isochromen-1-one **3a** (30% probability ellipsoids).

Using the optimal conditions, we then explored the substrate scope of this transformation. The results are summarized in Table 2. The substituents attached to the triple bond of 2-(2-alkynyl)benzoates 1 were tolerated well in general. For instance, when 2-alkynylbenzoate 1d, with an *n*-



butyl group attached to the alkynyl moiety, was used as the substrate, a high yield (94%) of product 3d was obtained. In contrast, substrate 1e, with a *tert*-butyl group, gave a 44% yield of 3e, probably due to steric hindrance. Interestingly, a trimethylsilyl group attached to the triple bond was tolerated under the standard conditions, and substrate 1g gave the desired product (i.e., 3g) in 85% yield. Additionally, various 2-alkynylbenzoates 1 with electron-withdrawing or electron-donating groups on the aromatic ring







worked well under the optimized conditions. Different functional groups including fluoro, methyl, and methoxy groups were all compatible with the reaction process (leading to 3j-3m). As expected, 3-phenyl-4-[(trifluoromethyl)thio]-1*H*isochromen-1-one (**3a**) was obtained in almost the same yield when methyl 2-(phenylethynyl)benzoate (**1a**) was replaced by ethyl 2-(phenylethynyl)benzoate (**1n**) under the standard conditions (Scheme 2).



Scheme 2. Reaction of ethyl 2-(phenylethynyl)benzoate (1n) with trifluoromethanesulfanylamide 2.

To investigate the reaction mechanism, we ran the reaction in the absence of trifluoromethanesulfanylamide 2 under the conditions shown in Table 2 (Scheme 3). Isocoumarin 4 was obtained by the Lewis acid (BiCl<sub>3</sub>) catalysed intramolecular annulation of the internal alkyne in 85% yield. Isocoumarin 4 was not transformed into the desired product (i.e., 3a) under the optimized conditions (Scheme 4). The formation of the trifluoromethylthio-substituted iso-



Scheme 3. Cyclization of methyl 2-(phenylethynyl)benzoate (1a) in the absence of trifluoromethanesulfanylamide 2.



Scheme 4. Cyclization of 3-phenyl-1H-isochromen-1-one (4) with trifluoromethanesulfanylamide 2.



Scheme 5. Proposed pathway for the formation of 3a.

# FULL PAPER

coumarin **3a** instead of **4** is probably due to the strong interaction between the trifluoromethanesulfanyl cation (CF<sub>3</sub>S<sup>+</sup>) and the carbon–carbon triple bond. Based on these preliminary results and previous studies,<sup>[5]</sup> we propose that the reaction involves a cascade electrophilic activation/cyclization process (Scheme 5). Initially, the additive BF<sub>3</sub>·Et<sub>2</sub>O promotes the generation of a reactive CF<sub>3</sub>S<sup>+</sup> cation and aniline (which was observed by TLC) from trifluoromethanesulfanylamide **2**.<sup>[5d]</sup> Subsequently, intermediate **A** would be formed by coordination between the carbon–carbon triple bond and the trifluoromethanesulfanyl cation (CF<sub>3</sub>S<sup>+</sup>). Then, the intermediate **B** would be produced by intramolecular nucleophilic attack of oxygen. Finally, S<sub>N</sub>2 attack of the chloride ion coming from BiCl<sub>3</sub> on the methyl group generates the desired product (i.e., **3**).<sup>[5k]</sup>

### Conclusions

We have reported a trifluoromethylthiolation/cyclization protocol for the synthesis of 4-[(trifluoromethyl)thio]-1*H*-isochromen-1-ones **3** through reaction of 2-(2-alkynyl)-benzoates **1** with trifluoromethanesulfanylamide **2** in good yields under mild conditions. The Lewis acids BiCl<sub>3</sub> and BF<sub>3</sub>·Et<sub>2</sub>O were found to be important as activators in the transformation. The introduction of a (trifluoromethyl)thio moiety (SCF<sub>3</sub>) into other heterocycles is currently underway in our laboratory.

### **Experimental Section**

General Information: Unless otherwise stated, commercially sourced reagents were used as received. Solvents were dried and distilled according to standard procedures. Flash column chromatography was carried out using silica gel (60 Å pore size, 32-63 µm, standard grade). Analytical thin-layer chromatography was carried out using glass plates precoated with 0.25 mm 230-400 mesh silica gel impregnated with a fluorescent indicator (254 nm). Thin-layer chromatography plates were visualized by exposure to ultraviolet light. Organic solutions were concentrated in rotary evaporators at ca. 20 Torr at 25-35 °C. <sup>1</sup>H, <sup>19</sup>F, and <sup>13</sup>C NMR spectra were recorded in CDCl<sub>3</sub> with a Bruker DRX-400 spectrometer operating at 400, 376, or 100 MHz, respectively. Chemical shifts are reported in parts per million (ppm) from internal tetramethylsilane on the  $\delta$  scale. Coupling constants are reported in Hz. High-resolution mass spectra (HRMS) were obtained with a micrOTOF II Instrument.

General Procedure for the Synthesis of 4-[(Trifluoromethyl)thio]-1*H*isochromen-1-ones: BiCl<sub>3</sub> (69.4 mg, 0.22 mmol) was added to a solution of 2-alkynylbenzoate 1 (0.2 mmol), trifluoromethanesulfanylamide 2 (0.3 mmol) and BF<sub>3</sub>·Et<sub>2</sub>O (0.3 mmol) in toluene (2.0 mL) under nitrogen. The mixture was stirred at 25 °C for 4– 6 h. After TLC showed that the reaction was complete, the mixture was filtered through a thin layer of silica gel, which was then washed with EtOAc ( $3 \times 5.0$  mL). The mixture was concentrated in vacuo, and the residue was purified by column chromatography on silica gel (eluting with petroleum ether/EtOAc, 20:1) to give product 3.

**3-Phenyl-4-[(trifluoromethyl)thio]-1***H*-isochromen-1-one (3a): White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.36 (dd, *J* = 7.9, 0.8 Hz,

1 H), 8.18 (d, J = 8.1 Hz, 1 H), 7.91–7.84 (m, 1 H), 7.68 (dd, J = 7.6, 1.8 Hz, 2 H), 7.62 (dd, J = 11.2, 4.0 Hz, 1 H), 7.48–7.50 (m, 3 H) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta = -42.41$  (s) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 163.5, 160.5, 137.7, 135.4, 132.3, 130.5, 129.8, 129.1, 128.9$  (q,  $J_{C,F} = 310.0$  Hz), 128.1, 127.3, 125.6, 120.3, 115.0 ppm. HRMS calcd. for  $C_{16}H_{10}F_3O_2S$  [M + H]<sup>+</sup> 323.0348; found 323.0322.

**3-**(*p*-Tolyl)-4-[(trifluoromethyl)thio]-1*H*-isochromen-1-one (3b): White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.35 (dd, J = 7.9, 0.9 Hz, 1 H), 8.17 (d, J = 8.1 Hz, 1 H), 7.88–7.84 (m, 1 H), 7.62–7.58 (m, 3 H), 7.29 (d, J = 8.0 Hz, 2 H), 2.43 (s, 3 H) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = -42.45 (s) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 163.8, 160.7, 141.0, 138.0, 135.4, 133.9, 131.7, 130.1, 129.9, 129.8, 129.0 (q,  $J_{C,F}$  = 310.0 Hz), 128.8, 125.6, 120.3, 21.5 ppm. HRMS calcd. for C<sub>17</sub>H<sub>12</sub>F<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 337.0505; found 337.0483.

**3-(4-Chlorophenyl)-4-[(trifluoromethyl)thio]-1***H*-isochromen-1-one (3c): White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.37 (dd, *J* = 7.6, 0.8 Hz, 1 H), 8.18 (d, *J* = 8.4 Hz, 1 H), 7.90 (t, *J* = 7.6 Hz, 1 H), 7.65–7.63 (m, 3 H), 7.48–7.46 (m, 2 H) ppm. <sup>19</sup>F NMR (375 MHz, CDCl<sub>3</sub>):  $\delta$  = 42.35 (s, 3 F) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 162.3, 160.3, 137.6, 136.9, 135.6, 131.3, 130.7, 130.0, 129.4, 128.8 (q, *J*<sub>C,F</sub> = 311 Hz), 128.5, 125.6, 120.4 ppm. HRMS calcd. for C<sub>16</sub>H<sub>9</sub>ClF<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 356.9958; found 356.9950.

**3-Butyl-4-[(trifluoromethyl)thio]**-1*H*-isochromen-1-one (**3**d): White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.29 (dd, *J* = 7.9, 0.9 Hz, 1 H), 8.05 (d, *J* = 8.1 Hz, 1 H), 7.85–7.80 (m, 1 H), 7.57–7.53 (m, 1 H), 3.02 (s, 2 H), 1.79–1.72 (m, 2 H), 1.47–1.41 (m, 2 H), 0.97 (t, *J* = 7.3 Hz, 3 H) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = -42.86 (s) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 168.0, 160.9, 141.3, 137.6, 135.4, 129.8, 129.1 (q, *J*<sub>C,F</sub> = 310.0 Hz), 128.5, 125.0, 120.1, 32.6, 29.4, 22.4, 13.7 ppm. HRMS calcd. for C<sub>14</sub>H<sub>14</sub>F<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 303.0661; found 303.0660.

**3**-(*tert*-**Butyl**)-4-[(trifluoromethyl)thio]-1*H*-isochromen-1-one (3e): White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.73 (d, *J* = 8.1 Hz, 1 H), 7.96 (d, *J* = 7.6 Hz, 1 H), 7.76 (td, *J* = 7.9, 1.2 Hz, 1 H), 7.63 (td, *J* = 7.5, 0.7 Hz, 1 H), 1.44 (s, 9 H) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = -41.26 (s) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 165.1, 153.8, 138.9, 134.8, 131.0, 127. 8 [q, *J*(C,F) = 310.0 Hz], 127.4, 125.6, 118.7, 38.8, 30.4 ppm. HRMS calcd. for C<sub>14</sub>H<sub>14</sub>F<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 303.0661; found 303.0664.

**3-(2-Methoxyphenyl)-4-[(trifluoromethyl)thio]-1***H*-isochromen-1-one (**3f**): White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.37 (dd, *J* = 7.9, 1.1 Hz, 1 H), 8.14 (d, *J* = 8.1 Hz, 1 H), 7.90–7.85 (m, 1 H), 7.64–7.60 (m, 1 H), 7.51–7.46 (m, 1 H), 7.41 (d, *J* = 7.3 Hz, 1 H), 7.07 (t, *J* = 7.4 Hz, 1 H), 6.99 (d, *J* = 8.4 Hz, 1 H), 3.82 (s, 3 H) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = -42.40 (s) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 161.2, 156.9, 137.7, 135.3, 132.0, 130.9, 129.9, 129.1 (q, *J* = 310.0 Hz), 129.0, 125.5, 121.9, 120.6, 120.3, 111.0, 55.6 ppm. HRMS calcd. for C<sub>17</sub>H<sub>12</sub>F<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 353.0454; found 353.0440.

**4-[(Trifluoromethyl)thio]-3-(trimethylsilyl)-1***H*-isochromen-1-one (3g): White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 8.31$  (dd, J = 8.0, 1.0 Hz, 1 H), 8.10 (d, J = 8.0 Hz, 1 H), 7.84 (t, J = 7.6 Hz, 1 H), 7.61 (t, J = 7.6 Hz, 1 H), 0.46 (s, 9 H) ppm. <sup>19</sup>F NMR (375 MHz, CDCl<sub>3</sub>):  $\delta = 41.93$  (s, 3 F) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 174.64, 161.66, 136.49, 135.01, 128.74$  ( $J_{C,F} = 310.0$  Hz), 124.90, 121.84, 121.21, 115.10, -0.51 ppm. HRMS calcd. for C<sub>13</sub>H<sub>14</sub>F<sub>3</sub>O<sub>2</sub>SSi [M + H]<sup>+</sup> 319.0430; found 319.0434.

**3-(4-Fluorophenyl)-4-[(trifluoromethyl)thio]-1***H***-isochromen-1-one** (**3h**): White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.36 (dd, *J* =

7.9, 1.0 Hz, 1 H), 8.18 (d, J = 8.2 Hz, 1 H), 7.91–7.87 (m, 1 H), 7.72–7.68 (m, 2 H), 7.66–7.61 (m, 1 H), 7.20–7.16 (m, 2 H) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta = -42.42$  (s), -108.99 (s) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 163.8$  (d, J = 252.3 Hz), 162.5, 160.4, 137.7, 135.5, 132.1 (d, J = 8.7 Hz), 129.9, 129.3, 128.8 (q, J =310.0 Hz), 128.4, 125.7, 120.3, 115.4 (d, J = 22.0 Hz) ppm. HRMS calcd. for C<sub>16</sub>H<sub>9</sub>F<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 341.0254; found 341.0248.

**7-Methoxy-3-phenyl-4-[(trifluoromethyl)thio]-1***H***-isochromen-1-one** (**3j**): White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.10 (d, *J* = 8.8 Hz, 1 H), 7.76 (d, *J* = 2.8 Hz, 1 H), 7.68–7.66 (m, 2 H), 7.50–7.43 (m, 4 H), 3.95 (s, 3 H) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = -42.43 (s) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 161.3, 160.8, 160.2, 132.3, 131.3, 130.3, 129.9, 129.0 (q, *J* = 310.0 Hz), 128.1, 127.5, 124.7, 123.4, 121.6, 110.4, 55.9 ppm. HRMS calcd. for C<sub>17</sub>H<sub>12</sub>F<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 353.0454; found 353.0457.

**7-Methyl-3-phenyl-4-[(trifluoromethyl)thio]-1***H***-isochromen-1-one (3k):** White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 8.25$  (d, J = 8.1 Hz, 1 H), 7.96 (s, 1 H), 7.68–7.65 (m, 2 H), 7.51–7.42 (m, 4 H), 2.57 (s, 3 H) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta = -42.45$  (s) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta = 163.7$ , 160.6, 146.8, 137.8, 132.4, 130.5, 129.9, 128.9 (q,  $J_{C,F} = 310$  Hz), 128.1, 125.7, 117.9, 22.3 ppm. HRMS calcd. for  $C_{17}H_{12}F_3O_2S$  [M + H]<sup>+</sup> 337.0505; found 337.0508.

**7-Fluoro-3-phenyl-4-[(trifluoromethyl)thio]-1***H*-isochromen-1-one **(3)**: White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 8.20$  (dd, J = 8.9, 4.9 Hz, 1 H), 8.01 (dd, J = 8.1, 2.7 Hz, 1 H), 7.67 (dd, J = 7.9, 1.7 Hz, 2 H), 7.61–7.57 (m, 1 H), 7.52–7.46 (m, 3 H) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta = -42.41$  (s, 3 F), –109.70 (s, 1 F) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 162.9$ , 162.4 (d, J = 250.0 Hz), 159.6, 134.3, 131.9, 130.7, 129.9, 128.8 (q, J = 311.0 Hz), 128.5 (d, J = 7.8 Hz), 128.2, 123.6 (d, J = 22.9 Hz), 122.1 (d, J = 8.3 Hz), 115.4 (d, J = 23.6 Hz) ppm. HRMS calcd. for C<sub>16</sub>H<sub>9</sub>F<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 341.0254; found 341.0252.

**6-Fluoro-3-phenyl-4-[(trifluoromethyl)thio]-1***H*-isochromen-1-one **(3m):** White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 8.39$  (dd, J = 8.7, 5.6 Hz, 1 H), 7.84 (dd, J = 9.9, 2.2 Hz, 1 H), 7.71–7.65 (m, 2 H), 7.55–7.46 (m, 3 H), 7.31 (ddd, J = 8.7, 8.0, 2.4 Hz, 1 H) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta = -42.4, -99.6$  ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 167.3$  (d, J = 257.6 Hz), 165.0, 159.6, 141.2 (d, J = 10.4 Hz), 133.3 (d, J = 10.3 Hz), 131.9 (d, J = 17.6 Hz), 130.8, 129.8, 128.8 (q,  $J_{C,F} = 311.0$  Hz), 128.7, 117.5 (d, J = 23.4 Hz), 116.8, 112.0 (d, J = 25.3 Hz) ppm. HRMS calcd. for C<sub>16</sub>H<sub>9</sub>F<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 341.0254; found 341.0246.

**Supporting Information** (see footnote on the first page of this article): <sup>1</sup>H, <sup>19</sup>F, and <sup>13</sup>C NMR spectra of compounds **3**.

### Acknowledgments

Financial support from the National Natural Science Foundation of China (21262016), the Project of Jiangxi Youth Scientist (20122BCB23012), the Jiangxi Educational Committee (GJJ12169), the Visiting Programme of Jiangxi Normal University graduate, and the Natural Science Foundation of Jiangxi Province of China (20133ACB20008, 20132BAB203006) is gratefully acknowledged.

For example, see: a) R. Filler, Y. Kobayashi, *Biomedicinal Aspects of Fluorine Chemistry*, Elsevier, Amsterdam, **1982**; b) J. T. Welch, S. Eswarakrishman (Eds.), *Fluorine in Bioorganic Chemistry*, Wiley, New York, **1991**; c) A. Becker, *Inventory of Industrial Fluoro-Biochemicals*, Eyrolles, Paris, **1996**; d) J.-P. Begue,



D. Bonnet-Delpon (Eds.), *Bioorganic and Medicinal Chemistry* of Fluorine, Wiley, Hoboken, **2008**; e) I. Ojima (Ed.), Fluorine in Medicinal Chemistry and Chemical Biology, Wiley, Chichester, **2009**.

- [2] a) F. Leroux, P. Jeschke, M. Schlosser, Chem. Rev. 2005, 105, 827; b) V. N. Boiko, Beilstein J. Org. Chem. 2010, 6, 880.
- [3] a) J. C. Biffinger, H. W. Kim, S. G. DiMagno, *ChemBioChem* 2004, 5, 622; b) P. Jeschke, *ChemBioChem* 2004, 5, 570; c) K. Muller, C. Faeh, F. Diederich, *Science* 2007, 317, 1881; d) J. Stetter, F. Lieb, *Angew. Chem. Int. Ed.* 2000, 39, 1724; *Angew. Chem.* 2000, 112, 1792; e) P. B. Curtis-Prior, M. Prouteau, *Int. J. Obesity* 1983, 7, 575; *Chem. Abstr.* 1984, 100, 61765; f) A. Haberkorn, H.-C. Mundt, *Prakt. Tierarzt* 1988, 69, 46.
- [4] a) G. Teverovskiy, D. S. Surryand, S. L. Buchwald, Angew. Chem. Int. Ed. 2011, 50, 7312; Angew. Chem. 2011, 123, 7450;
  b) C.-P. Zhang, D. A. Vicic, J. Am. Chem. Soc. 2012, 134, 183;
  c) C.-P. Zhang, D. A. Vicic, Chem. Asian J. 2012, 7, 1756; d)
  Z. Weng, W. He, C. Chen, R. Lee, D. Tan, Z. Lai, D. Kong, Y. Yuan, K.-W. Huang, Angew. Chem. Int. Ed. 2013, 52, 1548; Angew. Chem. 2013, 125, 1588; e) Q. Xiao, J. Sheng, Q. Ding, J. Wu, Eur. J. Org. Chem. 2014, 217; f) X. Wang, Y. Zhou, G. Ji, G. Wu, M. Li, Y. Zhang, J. Wang, Eur. J. Org. Chem. 2014, 3093.
- [5] a) A. Ferry, T. Billard, B. R. Langlois, E. Bacqué, J. Org. Chem. 2008, 73, 9362; b) A. Ferry, T. Billard, B. R. Langlois, E. Bacqué, Angew. Chem. Int. Ed. 2009, 48, 8551; Angew. Chem. 2009, 121, 8703; c) A. Ferry, T. Billard, E. Bacqué, B. R. Langlois, J. Fluorine Chem. 2012, 134, 160; d) Y. Yang, X. Jiang, F.-L. Qing, J. Org. Chem. 2012, 77, 7538; e) F. Baert, J. Colomb, T. Billard, Angew. Chem. Int. Ed. 2012, 51, 10382; Angew. Chem. 2012, 124, 10528; f) J. Liu, L. Chu, F.-L. Qing, Org. Lett. 2013, 15, 894; g) S. Alazet, L. Zimmer, T. Billard, Angew. Chem. Int. Ed. 2013, 49, 8647; i) J. Sheng, Z. Chen, J. Wu, Chem. Commun. 2013, 49, 8647; i) J. Sheng, S. Li, J. Wu, Chem. Commun. 2014, 50, 578; j) S. Alazet, K. Ollivier, T. Billard, Beilstein J. Org. Chem. 2013, 9, 2354; k) J. Sheng, C. Fan, J. Wu, Chem. Commun. 2014, 50, 5494.
- [6] a) X. Shao, X. Wang, T. Yang, L. Lu, Q. Shen, Angew. Chem. Int. Ed. 2013, 52, 3457; Angew. Chem. 2013, 125, 3541; b) X.
  Wang, T. Yang, X. Cheng, Q. Shen, Angew. Chem. Int. Ed. 2013, 52, 12860; c) Q.-H. Deng, C. Rettenmeier, H. Wadepohl, L. Gade, Chem. Eur. J. 2014, 20, 93; d) E. V. Vinogradova, P.
  Müller, S. L. Buchwald, Angew. Chem. Int. Ed. 2014, 53, 3125; Angew. Chem. 2014, 126, 3189.
- [7] Y. Yang, A. Azuma, E. Tokunaga, M. Yamasaki, M. Shiro, N. Shibata, J. Am. Chem. Soc. 2013, 135, 8782.
- [8] a) T. Bootwicha, X. Liu, R. Pluta, I. Atodiresei, M. Ruepin, Angew. Chem. Int. Ed. 2013, 52, 12856; b) M. Rueping, X. Liu, T. Bootwicha, R. Pluta, C. Merkens, Chem. Commun. 2014, 50, 2508; c) R. Pluta, P. Nikolaienko, M. Rueping, Angew. Chem. Int. Ed. 2014, 53, 1650; d) C. Xu, Q. Shen, Org. Lett. 2014, 16, 2046.
- [9] a) C. Chen, Y. Xie, L. Chu, R.-W. Wang, X. Zhang, F.-L. Qing, Angew. Chem. Int. Ed. 2012, 51, 2492; Angew. Chem. 2012, 124, 2542; b) C. Chen, L. Chu, F.-L. Qing, J. Am. Chem. Soc. 2012, 134, 12454; c) A. Tlili, T. Billard, Angew. Chem. Int. Ed. 2013, 52, 6818; Angew. Chem. 2013, 125, 6952.
- [10] L. D. Tran, I. Popov, O. Daugulis, J. Am. Chem. Soc. 2012, 134, 18237.
- [11] F. Yin, X.-S. Wang, Org. Lett. 2014, 16, 1128.
- [12] a) R. D. Barry, *Chem. Rev.* 1964, 64, 229; b) E. Napolitano, *Org. Prep. Proced. Int.* 1997, 29, 631; c) S. Pal, V. Chatare, M. Pal, *Curr. Org. Chem.* 2011, 15, 782; d) K. M. Meepagala, G. Sturtz, D. E. Wedge, *J. Agric. Food Chem.* 2002, 50, 6989; e) D. Engelmeier, F. Hadacek, O. Hofer, G. Lutz-Kutschera, M. Nagl, G. Wurz, H. Greger, *J. Nat. Prod.* 2004, 67, 19.
- [13] For example, see: a) B. Chen, S. Ma, Org. Lett. 2013, 15, 3884;
  b) R. C. Larock, T. Hightower, J. Org. Chem. 1993, 58, 5298;
  c) D. E. Korte, L. S. Hegedus, R. K. Wirth, J. Org. Chem. 1977, 42, 1329;
  d) Y. He, X. Zhang, N. Shen, X. Fan, J. Org. Chem.

## FULL PAPER

**2013**, *78*, 1017; e) V. Kavala, C.-C. Wang, D. Barange, C.-W. Kuo, P.-M. Lei, C.-F. Yao, *J. Org. Chem.* **2012**, *77*, 5022; f) D. Nandi, D. Ghosh, S.-J. Chen, B.-C. Kuo, N. Wang, H. Lee, *J. Org. Chem.* **2013**, *78*, 3445; g) Z.-Y. Ge, X.-D. Fei, T. Tang, Y.-M. Zhu, J.-K. Shen, *J. Org. Chem.* **2012**, *77*, 5736; h) C. Sun, Y. Fang, S. Li, Y. Zhang, Q. Zhao, S. Zhu, C. Li, *Org. Lett.* **2009**, *11*, 4084; i) L. Liu, J. Hu, X.-C. Wang, M.-J. Zhong, X.-Y. Liu, S.-D. Yang, Y.-M. Liang, *Tetrahedron* **2012**, *68*, 5391; j) K. Cherry, J.-L. Parrain, J. Thibonnet, M. Abarbri, *J. Org. Chem.* **2005**, *70*, 6669; k) X. Fan, Y. He, L. Cui, S. Guo, J.

Wang, X. Zhang, *Eur. J. Org. Chem.* **2012**, 77, 673; 1) S. Cai, F. Wang, C. Xi, *J. Org. Chem.* **2012**, 77, 2331; m) T. Yao, R. C. Larock, *J. Org. Chem.* **2003**, 68, 5936; n) J. H. Park, S. V. Bhilare, S. W. Youn, *Org. Lett.* **2011**, *13*, 2228; o) A. K. Verma, V. Rustagi, T. Aggarwal, A. P. Singh, *J. Org. Chem.* **2010**, 75, 7691.

[14] G. Li, D. Li, Q. Xie, Y. Shi, S. Jiang, Y. Jin, J. Gene Med. 2008, 10, 1039 and references cited therein.

Received: May 25, 2014 Published Online: July 11, 2014